FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Tempus AI, Inc. Stock AnalysisComprehensive stock analysis for Tempus AI, Inc. (TEM) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTEM
TEM
Tempus AI, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TEM
Home🔹Stocks🔹Tempus AI, Inc.

Tempus AI, Inc.

🇺🇸TEM•NASDAQ

Tempus AI, Inc.

🇺🇸TEM•NASDAQ
Market cap
$10.34B
Sentiment

Your view on TEM

Mkt Cap
$10.34B
Sentiment
Your view
TEM
Tempus AI, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TEM
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Tempus AI, Inc.

Industry
Medical - Healthcare Information Services
Sector
Healthcare
CEO
Eric Lefkofsky
Headquarters
US
Industry
Medical - Healthcare Information Services
Sector
Healthcare
CEO
Eric Lefkofsky
Headquarters
US
Description

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.

The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies.

In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data.

The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Tempus AI, Inc., and the rating behind it. TEM last traded at $59.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Tempus AI, Inc.. Starting points for Tempus AI, Inc.: EPS -$1.41, beta 3.72 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Tempus AI, Inc.. Tempus AI, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Tempus AI, Inc.. Trailing twelve-month EPS for Tempus AI, Inc. stands at -$1.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Tempus AI, Inc.. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Tempus AI, Inc. valued side by side against its closest peers. Tempus AI, Inc. is measured against Medical - Healthcare Information Services peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Tempus AI, Inc., and how their positions are changing. At a $10.34B market value, institutional positions materially move Tempus AI, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Tempus AI, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Tempus AI, Inc.. Tempus AI, Inc. is a $10.34B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Tempus AI, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Tempus AI, Inc.. Coverage tracks Tempus AI, Inc. within Medical - Healthcare Information Services (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • CNC — Centene Corporation
  • COO — The Cooper Companies, Inc.
  • DOCS — Doximity, Inc.
  • FMS — Fresenius Medical Care AG & Co. KGaA
  • ICLR — ICON Public Limited Company
  • MEDP — Medpace Holdings, Inc.
  • NBIX — Neurocrine Biosciences, Inc.

More Medical - Healthcare Information Services companies

  • XSVT — Xsovt Brands, Inc.
  • ZCMD — Zhongchao Inc.
  • PASO — Patient Access Solutions, Inc.
  • PCK.AX — PainChek Limited
  • PHR — Phreesia, Inc.
  • PIAHY — Ping An Healthcare and Technology Company Limited
  • PINC — Premier, Inc.
  • PKY.AX — Pathkey.AI Ltd
  • PMCUF — Pro Medicus Limited
  • PME.AX — Pro Medicus Limited
  • PPJE — PPJ Healthcare Enterprises, Inc.
  • PPRG — Patient Portal Technologies, Inc.

ETFs holding Tempus AI, Inc.

  • ARKG — ARK Genomic Revolution ETF (7.67%)
  • ARKK — ARK Innovation ETF (4.83%)
  • ULTI — REX IncomeMax Option Strategy ETF (4.78%)
  • HEAL — Global X - HealthTech ETF (4.01%)
  • EKG — First Trust Nasdaq Lux Digital Health Solutions ETF (3.32%)
  • THNQ — ROBO Global Artificial Intelligence ETF (2.73%)

News

Latest Market News